Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ABBV-151 + ABBV-181 |
Synonyms | |
Therapy Description |
Limited information is currently available on ABBV-151 (Feb, 2019). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-151 | ARGX-115|ABBV151|ABBV 151 | ABBV-151 is a monoclonal antibody against glycoprotein A repetitions predominant (GARP), which prevents release of transforming growth factor beta (NCI Drug Dictionary). | ||
ABBV-181 | ABBV181|ABBV 181|Budigalimab | Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 67 | ABBV-181 (budigalimab) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32770720). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03821935 | Phase I | ABBV-151 ABBV-151 + ABBV-181 | Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | CAN | 9 |